Imperial College London


Faculty of MedicineSchool of Public Health

Professor of Global Health



+44 (0)20 7594 1150timothy.hallett




Norfolk PlaceSt Mary's Campus






BibTex format

author = {Nayagam, S and Sicuri, E and Lemoine, M and Easterbrook, P and Conteh, L and Hallett, TB and Thursz, M},
doi = {10.1186/s12879-017-2778-x},
journal = {BMC Infectious Diseases},
pages = {107--116},
title = {Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries},
url = {},
volume = {17},
year = {2017}

RIS format (EndNote, RefMan)

AB - Background: Many people living with chronic HBV infection remain undiagnosed until later stages of disease.Increasing testing and treatment rates form part of the strategy to respond to the WHO goal of eliminating viralhepatitis as a public health threat by 2030. However, achieving these ambitious targets is dependent on findingeffective and cost-effective methods of scale up strategies. The aim of this study was to undertake a narrativereview of the literature on economic evaluations of testing and treatment for HBV infection, to help inform thedevelopment of the 2017 WHO Hepatitis Testing Guidelines.Methods: We undertook a focussed literature review for economic evaluations on testing for HBV accompanied byantiviral treatment. The search was carried out in Pubmed and included only articles published after 2000 and writtenin English. We narratively synthesise the results and discuss the key drivers of cost-effectiveness and their applicabilityto low and middle-income countries (LMICs).Results: Nine published studies were included in this review, only one of which was performed in a low or middleincomesetting in West Africa. Eight studies were performed in high-income settings, seven among high risk groupsand one among the general population. The studies were heterogeneous in many respects including the populationand testing strategy under consideration, model structure and baselines parameters, willingness to pay thresholds andoutcome measures used. However, most studies found HBV testing and treatment to be cost-effective, even at lowHBsAg prevalence levels.Conclusions: Currently economic evaluations of HBV testing and treatment strategies in LMICs is lacking, thereforelimiting the ability to provide formal recommendations on the basis of cost-effectiveness alone. Further implementationresearch is needed in order to help guide national policy planning.
AU - Nayagam,S
AU - Sicuri,E
AU - Lemoine,M
AU - Easterbrook,P
AU - Conteh,L
AU - Hallett,TB
AU - Thursz,M
DO - 10.1186/s12879-017-2778-x
EP - 116
PY - 2017///
SN - 1471-2334
SP - 107
TI - Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries
T2 - BMC Infectious Diseases
UR -
UR -
VL - 17
ER -